In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Dan Schulman
Advertisement
Dan Schulman is a partner at Beghou Consulting.
Articles by Dan Schulman
As biopharma companies eye product launches in a commercial environment that has been transformed by the COVID-19 pandemic, they must adjust their launch preparations to account for a more complex, fragmented and dynamic landscape.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
Could DTC Programs Help Simplify the Drug-Pricing System?
5
